参考文献: |
1. De Santi C, et al. Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone. Eur J Clin Pharmacol, 1998, 54(3), 215-219. 2. Di Giovanni S, et al. Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J Biol Chem, 2010, 285(20), 14941-14954. 3. Jenner P, et al. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology, 2004, 62(1 Suppl 1), S47-55. 4. Hamaue N, et al. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus. Brain Res, 2010, 1309, 110-115. 5. Peng S, et al. Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1. Sci Transl Med. 2019 Apr 17;11(488):eaa |